Firefly Neuroscience Successfully Deploys NVIDIA L40S GPU Acceleration to Power Next-Gen ‘CLEAR’ Platform
Firefly Neuroscience (NASDAQ: AIFF) has announced the successful deployment of its new 'CLEAR' (CLeaning EEG ARtifacts) Platform, powered by NVIDIA L40S GPU technology. The platform represents a significant advancement in EEG data preprocessing, achieving 60-80% faster processing times while maintaining high signal quality.
The CLEAR Platform utilizes state-of-the-art signal processing and machine learning techniques to clean EEG recordings from various artifacts, including muscle activity and environmental interference. This technology enhancement enables better detection of neural biomarkers crucial for neurological and psychiatric condition diagnosis and treatment.
This development follows Firefly's recent acceptance into the NVIDIA Connect Program and leverages the company's position as owner of the world's largest standardized EEG/ERP repository.
Firefly Neuroscience (NASDAQ: AIFF) ha annunciato il lancio con successo della sua nuova piattaforma 'CLEAR' (CLeaning EEG ARtifacts), potenziata dalla tecnologia GPU NVIDIA L40S. La piattaforma segna un progresso rilevante nella pre-elaborazione dei dati EEG, garantendo tempi di elaborazione dal 60% all'80% più rapidi pur mantenendo elevata la qualità del segnale.
La CLEAR sfrutta avanzate tecniche di elaborazione del segnale e di machine learning per rimuovere artefatti dalle registrazioni EEG — tra cui attività muscolare e interferenze ambientali. Questo miglioramento tecnologico facilita l'individuazione di biomarcatori neurali fondamentali per la diagnosi e il trattamento di patologie neurologiche e psichiatriche.
Lo sviluppo segue la recente ammissione di Firefly al NVIDIA Connect Program e si avvantaggia della posizione dell'azienda come proprietaria del più grande repository standardizzato al mondo di EEG/ERP.
Firefly Neuroscience (NASDAQ: AIFF) ha anunciado el despliegue exitoso de su nueva plataforma 'CLEAR' (CLeaning EEG ARtifacts), impulsada por la tecnología GPU NVIDIA L40S. La plataforma supone un avance importante en el preprocesamiento de datos EEG, logrando tiempos de procesamiento un 60-80% más rápidos sin sacrificar la calidad de la señal.
CLEAR utiliza técnicas de procesamiento de señales y aprendizaje automático de última generación para limpiar las grabaciones EEG de diversos artefactos, incluida la actividad muscular y las interferencias ambientales. Esta mejora tecnológica permite una mejor detección de biomarcadores neuronales clave para el diagnóstico y tratamiento de trastornos neurológicos y psiquiátricos.
Este desarrollo se produce tras la reciente incorporación de Firefly al NVIDIA Connect Program y aprovecha la posición de la compañía como propietaria del mayor repositorio estandarizado de EEG/ERP del mundo.
Firefly Neuroscience (NASDAQ: AIFF)는 NVIDIA L40S GPU 기술로 구동되는 새로운 'CLEAR' (CLeaning EEG ARtifacts) 플랫폼의 성공적 도입을 발표했습니다. 이 플랫폼은 EEG 데이터 전처리에서 중요한 진전을 의미하며, 신호 품질을 유지하면서도 처리 속도가 60–80% 빨라졌습니다.
CLEAR 플랫폼은 최첨단 신호 처리 및 머신러닝 기법을 활용해 근육 활동이나 환경 잡음 등 다양한 아티팩트로부터 EEG 기록을 정리합니다. 이 기술 향상은 신경학적·정신과적 질환의 진단과 치료에 중요한 신경 바이오마커를 더 잘 검출할 수 있게 합니다.
이번 개발은 Firefly가 최근 NVIDIA Connect Program에 선정된 데 따른 것이며, 세계에서 가장 큰 표준화된 EEG/ERP 저장소의 소유주라는 회사의 지위를 활용합니다.
Firefly Neuroscience (NASDAQ: AIFF) a annoncé le déploiement réussi de sa nouvelle plateforme 'CLEAR' (CLeaning EEG ARtifacts), propulsée par la technologie GPU NVIDIA L40S. La plateforme représente une avancée significative dans le prétraitement des données EEG, atteignant des temps de traitement 60 à 80 % plus rapides tout en maintenant une qualité de signal élevée.
CLEAR utilise des techniques de traitement du signal et d'apprentissage automatique de pointe pour nettoyer les enregistrements EEG des divers artefacts, notamment l'activité musculaire et les interférences environnementales. Cette amélioration technologique permet une meilleure détection des biomarqueurs neuronaux essentiels au diagnostic et au traitement des troubles neurologiques et psychiatriques.
Ce développement fait suite à l'acceptation récente de Firefly dans le NVIDIA Connect Program et s'appuie sur la position de l'entreprise en tant que propriétaire du plus grand dépôt standardisé EEG/ERP au monde.
Firefly Neuroscience (NASDAQ: AIFF) hat die erfolgreiche Einführung seiner neuen 'CLEAR' (CLeaning EEG ARtifacts) Plattform bekanntgegeben, die von NVIDIA L40S-GPU-Technologie angetrieben wird. Die Plattform stellt einen bedeutenden Fortschritt in der Vorverarbeitung von EEG-Daten dar und erzielt 60–80% schnellere Verarbeitungszeiten, bei gleichbleibend hoher Signalqualität.
CLEAR nutzt moderne Signalverarbeitungs- und Machine-Learning-Verfahren, um EEG-Aufzeichnungen von verschiedenen Artefakten wie Muskelaktivität und Störrauschen zu bereinigen. Diese technologische Verbesserung ermöglicht eine bessere Erkennung neuronaler Biomarker, die für die Diagnose und Behandlung neurologischer und psychiatrischer Erkrankungen wichtig sind.
Die Entwicklung folgt auf Fireflys jüngste Aufnahme in das NVIDIA Connect Program und nutzt die Position des Unternehmens als Eigentümer des weltweit größten standardisierten EEG/ERP-Repositorys.
- None.
- None.
Insights
Firefly's new CLEAR Platform leverages NVIDIA GPUs for faster, cleaner EEG processing, potentially accelerating brain biomarker discovery for neurological disorders.
Firefly Neuroscience has unveiled its next-generation 'CLEAR' (CLeaning EEG ARtifacts) Platform, a significant technological advancement that directly addresses one of the fundamental challenges in neurological research: noisy EEG data. By leveraging NVIDIA's L40S GPU with Ada Lovelace architecture, Firefly has achieved 60-80% improvement in processing times while simultaneously enhancing signal quality.
This development represents a critical infrastructure improvement for Firefly's core technology. EEG signals are notoriously susceptible to contamination from muscle activity, eye movements, and environmental interference. The CLEAR Platform applies advanced signal processing and machine learning techniques to filter these artifacts, resulting in cleaner data that can reveal subtle neural biomarkers previously obscured by noise.
The technology breakthrough has three key implications:
- It enhances Firefly's ability to identify novel brain biomarkers from their proprietary database (reportedly the world's largest standardized EEG/ERP repository)
- It accelerates preprocessing workflows, enabling faster analysis and potentially shorter research cycles
- It provides a foundation for developing what the company calls a "foundation model of the human brain"
This deployment comes shortly after Firefly's acceptance into the NVIDIA Connect Program, suggesting a strategic partnership that gives the company access to advanced computational resources. By improving both the speed and quality of EEG preprocessing, Firefly positions itself to enhance its pharmaceutical R&D partnerships and clinical development capabilities.
The timing is significant as interest in brain-computer interfaces and neurological biomarkers continues to grow across both clinical and research settings. Firefly's strategy appears focused on establishing their platform as essential infrastructure for translating complex neurological data into actionable clinical insights.
– Unlocks exciting new AI-driven brain biomarker discovery and advancement capabilities –
– Substantial processing speed gains while maintaining high signal quality standards –
– Comes just months after Firefly announced its acceptance into the NVIDIA Connect Program –
KENMORE, Wash. and NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to unveil its new ‘CLEAR’ (CLeaning EEG ARtifacts) Platform, a proprietary next-generation preprocessing technology designed to deliver unrivalled electroencephalogram (EEG) data quality. The CLEAR Platform was developed using NVIDIA’s L40S GPU with Ada Lovelace architecture.
EEG recordings are notoriously noisy, often contaminated by artifacts such as muscle activity, eye blinks, and environmental interference. The Company’s new CLEAR Platform uses state-of-the-art signal processing and machine learning techniques to ensure cleaner, more reliable data – paving the way for novel and scalable clinical insights. In validation testing, the CLEAR Platform demonstrated substantial increases in data quality. By improving the fidelity of EEG signals, researchers and clinicians are now empowered to detect subtle neural biomarkers critical for advancing diagnosis, treatment, and monitoring of neurological and psychiatric conditions.
Leveraging NVIDIA GPU acceleration, Firefly has also optimized the CLEAR Platform’s performance, achieving 60
“Data quality is the foundation of clinical insight,” said Gil Issachar, Firefly’s Chief Technology Officer. “By combining our advanced preprocessing methods with NVIDIA GPU acceleration, the CLEAR Platform represents the achievement of a key milestone along our path of building a foundation model of the human brain – unlocking exciting new AI-driven biomarker discovery capabilities and, thereby, accelerating the translation of EEG into actionable tools for patient care.”
Greg Lipschitz, Chief Executive Officer of Firefly, said, “The launch of our CLEAR Platform will serve as a key part of Firefly’s growth strategy, helping us achieve our mission to harness the power of AI and EEG to transform neuroscience and clinical development. With a robust foundation of clean data, the Company is poised to continue to discover and advance breakthrough cognitive brain biomarkers that can support pharmaceutical R&D, clinical trials, and ultimately, patient care.”
About Firefly
Firefly (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA™) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNA™ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use.
Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly’s extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNA™, in conjunction with an FDA-cleared EEG/ERP system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician’s ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient’s outcome.
Please visit https://fireflyneuro.com/ for more information.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly’s management teams’ expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to those factors described under the heading “Risk Factors” in the reports and other filings of Firefly with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Investor & Media Contact
Stephen Kilmer
(646) 274-3580
stephen.kilmer@fireflyneuro.com
FAQ
What is Firefly Neuroscience's CLEAR Platform and how does it improve EEG data processing?
How does NVIDIA's L40S GPU technology benefit Firefly's CLEAR Platform (NASDAQ: AIFF)?
What are the clinical applications of Firefly Neuroscience's CLEAR Platform?
How does Firefly's CLEAR Platform contribute to brain health research?
What is the significance of Firefly's EEG/ERP database?
